Myezom 2mg Injection

About

Bortezomib is a potent and reversible inhibitor of the 26S proteasome, a crucial multi-catalytic proteinase complex responsible for degrading ubiquitinated proteins within cells. By inhibiting the proteasome, bortezomib effectively disrupts cellular protein homeostasis, leading to an accumulation of misfolded and regulatory proteins. This accumulation triggers significant endoplasmic reticulum stress, activates intrinsic pro-apoptotic pathways, and ultimately induces programmed cell death specifically in malignant cells, particularly plasma cells which are highly sensitive to proteasome inhibition. This targeted action makes it a cornerstone therapy. It is primarily utilized in the treatment of multiple myeloma and mantle cell lymphoma, where its targeted mechanism has demonstrated significant and sustained clinical efficacy, often in combination with other agents, improving patient outcomes.

Uses

• Treatment of multiple myeloma.
• Management of mantle cell lymphoma.
• Used in patients who have received prior therapy.
• Can be used as initial therapy in certain cases.

Directions For Use

Administered subcutaneously or intravenously by a healthcare professional. Dosage and schedule are tailored to the specific condition and patient response.

Benefits

• Effective against multiple myeloma.
• Proven efficacy in mantle cell lymphoma.
• Can be used in relapsed or refractory settings.
• Targets specific pathways in cancer cells.
• Available for both subcutaneous and intravenous administration.
• May improve overall survival in eligible patients.

Side Effects

• Peripheral neuropathy
• Thrombocytopenia
• Neutropenia
• Fatigue
• Nausea and vomiting
• Diarrhea or constipation
• Fever
• Anemia
• Rash
• Muscle weakness
• Hypotension
• Herpes zoster reactivation

Safety Measures

• Alcohol - Avoid alcohol as it may worsen peripheral neuropathy or contribute to liver toxicity.
• Pregnancy - Contraindicated in pregnancy due to potential teratogenic effects. Use effective contraception during and after treatment.
• Breastfeeding - Not recommended during breastfeeding due to the potential for serious adverse reactions in the infant.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustments are typically required.
• Kidney - No dose adjustment is generally needed for renal impairment, but caution is advised in severe cases.
• Lung - Rare but serious acute diffuse infiltrative pulmonary disease can occur; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.